Clinical Trial Sees Rectal Cancer Remission for All Participants
A small clinical trial in New York City sent rectal cancer into remission for every patient that was involved by using a unique immunotherapeutic treatment.
The trial gave all the patients involved the immunotherapy treatment "Dostarlimab,” which then stunned doctors as it returned a 100% success rate for all patients in clinical trials. The immunotherapy had shrunk the tumors the patients had much quicker than the medical professionals were expecting.
The treatment was being tested for colorectal cancer. The trial was backed by drugmaker GlaxoSmithKline and was led by doctors at the Memorial Sloan Kettering Cancer Center.
One of the paper's authors, Dr. Luis A. Diaz, told The New York Times that he "believes this is the first time this has happened in the history of cancer.” Other experts said that the trial needs to be replicated. (JPost / VFI News)
The Lord sustains him on his sickbed; in his illness you restore him to full health. - Psalm 41:3